Neoadjuvant Immunotherapy Appears Promising for Muscle-Invasive Bladder Cancer
Neoadjuvant immunotherapy is an attractive alternative to chemotherapy for patients with localized MIBC because of its lower toxicity profile.
Neoadjuvant immunotherapy is an attractive alternative to chemotherapy for patients with localized MIBC because of its lower toxicity profile.
Patient comorbidities were among the significant risk factors for kidney function decline.
Investigators report findings from a retrospective study of 13,081 patients undergoing radical cystectomy.
The optimal duration of antibiotic prophylaxis is still unknown.
Study findings suggest that chemoradiation therapy could be considered an alternative to surgery in this patient population.
Provider training on female reproductive organ-sparing and nerve-sparing radical cystectomy needs to improve, according to investigators.
Swedish studies reveal significantly elevated risks for myocardial infarction, ischemic stroke, pulmonary embolism, and deep vein thrombosis.
Findings are from a case series of men who underwent cystoprostatectomy in China.
Acute kidney injury frequently occurs during neoadjuvant chemotherapy in patients with muscle-invasive bladder cancer.
Postoperative opioid prescriptions are associated with delayed recovery, perioperative complications, and opioid misuse, investigators noted.